Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma

Background: In vitro data demonstrated a dose-response relationship for doxorubicin in ovarian cancer (OC) cell lines. However, this dose-response question for doxorubicin was never carefully addressed in OC patients. These data and the more favorable toxicity profile of the anthracycline analogue e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology 1999-01, Vol.57 (1), p.10-16
Hauptverfasser:	Vermorken, J.B., ten Bokkel Huinink, W.W., Kobierska, A., van der Burg, M.E.L., Forni, M., Piccart, M.J., van der Putten, E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - adverse effects Antibiotics, Antineoplastic - therapeutic use Antineoplastic Agents - therapeutic use Biological and medical sciences Cisplatin - therapeutic use Clinical Study Drug Administration Schedule Epirubicin - administration & dosage Epirubicin - adverse effects Epirubicin - therapeutic use Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Leukopenia - chemically induced Medical sciences Middle Aged Ovarian Neoplasms - drug therapy Thrombocytopenia - chemically induced Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: In vitro data demonstrated a dose-response relationship for doxorubicin in ovarian cancer (OC) cell lines. However, this dose-response question for doxorubicin was never carefully addressed in OC patients. These data and the more favorable toxicity profile of the anthracycline analogue epirubicin prompted us to study high-dose epirubicin (HDE) in relapsed OC patients. Patients and Methods: This phase I study included 19 OC patients with measurable or evaluable disease and no more than one prior (cisplatin-containing) chemotherapy regimen. Dose escalation was not allowed in individual patients. Epirubicin was administered by rapid intravenous infusion (
ISSN:	0030-2414 1423-0232
DOI:	10.1159/000011994